NLS Agreement

Hansa Biopharma and SERB S.A. have announced an exclusive licensing agreement for development and commercialization of IDEFIRIX (imlifidase) in the European Union (EU), United Kingdom (UK), Switzerland, Norway, Liechtenstein, Iceland and MENA (Middle East and North Africa) regions.

The partnership will apply advanced AI capabilities to analyse complex datasets, identify promising drug candidates, and reduce the time required to move from research to patient, the company states.

Genovis has entered into a non-exclusive, worldwide license agreement with a US-based private biotech company, granting rights to use Genovis’ EndoS2 enzyme technology for the research, development, manufacture, and commercialization of antibody-drug conjugate (ADC) therapeutics.

Mendus has entered into an agreement with the Olivia Newton-John Cancer Research Institute (ONJCRI), an Australian cancer research institute, to support the DIVA trial with the company’s lead product vididencel in acute myeloid leukemia (AML).

A Letter of Intent (LOI) has been signed with SHINE Technologies as an additional supplier of non-carrier-added Lutetium-177 (n.c.a. Lu-177).

Suzhou Ribo Life Science and its Swedish subsidiary Ribocure Pharmaceuticals have entered into an exclusive worldwide licensing agreement with Madrigal Pharmaceuticals for six pre-clinical small interfering RNA (siRNA) programs for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).